Key Novo Nordisk A/S Financials
| Company Type | Public -(OMX Copenhagen: NOVO B) Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2000 Sales (mil.) | $2,601.5 |
| 2010 Employees | 30,483 |
Novo Nordisk A/S Stock Quote (NYSE: NVO)(OMX Copenhagen: NOVO B)
| Latest 02/15/12 16:02:17 EST | Change ($) | Change (%) | High | Low |
|---|---|---|---|---|
| $138.11 |  2.110 | 1.550 | $139.83 | $136.93 |
Quotes delayed 15 minutes for NASDAQ, 20 minues for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions. |
Novo Nordisk A/S Income Statement
| Dec 00 | Dec 99 | Dec 87 | |
| Revenue | 2,601.5 | 2,845.8 | 824.7 |
| Cost of Goods Sold | 547.4 | 686.1 | -- |
| Gross Profit | 2,054.1 | 2,159.7 | 824.7 |
| Gross Profit Margin | 79% | 75.9% | -- |
| SG&A Expense | 991.5 | 1,018.6 | -- |
| Depreciation & Amortization | 129.3 | 193.9 | -- |
| Operating Income | 530.3 | -- | -- |
| Operating Margin | 20.4% | --% | --% |
| Nonoperating Income | 46.1 | 79.4 | -- |
| Nonoperating Expenses | -- | -- | -- |
| Income Before Taxes | -- | -- | -- |
| Income Taxes | 219.5 | 209.9 | -- |
| Net Income After Taxes | (219.5) | (209.9) | 0.0 |
| Continuing Operations | 386.0 | 327.5 | -- |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 386.0 | 327.5 | -- |
| Total Net Income | 386.0 | 327.5 | 78.8 |
| Net Profit Margin | 14.8% | 11.5% | 9.6% |
| Diluted EPS from Total Net Income | 0.56 | 0.46 | 0.77 |
| Dividends per Share | 0.11 | -- | 0.10 |
All amounts in millions of US Dollars except per share amounts.
Novo Nordisk A/S Balance Sheet
| Assets | Dec 00 | Dec 99 | Dec 87 |
| Current Assets | |||
| Cash | 159.4 | 268.2 | 335.9 |
| Net Receivables | 588.5 | 887.0 | -- |
| Inventories | 496.2 | 664.0 | -- |
| Other Current Assets | 321.8 | 345.6 | -- |
| Total Current Assets | 1,565.9 | 2,164.7 | 687.7 |
| Net Fixed Assets | 1,362.4 | 1,998.0 | -- |
| Other Noncurrent Assets | 146.4 | 55.2 | -- |
| Total Assets | 3,074.6 | 4,218.0 | 1,356.0 |
| Liabilities | Dec 00 | Dec 99 | Dec 87 |
| Current Liabilities | |||
| Accounts Payable | 122.3 | 136.6 | -- |
| Short-Term Debt | 102.3 | -- | -- |
| Other Current Liabilities | 577.4 | 755.4 | -- |
| Total Current Liabilities | 802.0 | 892.0 | 347.4 |
| Long-Term Debt | 118.3 | -- | 144.4 |
| Other Noncurrent Liabilities | 186.5 | 804.6 | -- |
| Total Liabilities | 1,106.7 | 1,696.6 | -- |
| Shareholder's Equity | |||
| Preferred Stock Equity | -- | -- | -- |
| Common Stock Equity | 1,967.9 | 2,521.3 | -- |
| Total Equity | 1,967.9 | 2,521.3 | 847.3 |
| Shares Outstanding (thou.) | 600,000.0 | 634,000.0 | 102.0 |
All amounts in millions of US Dollars except per share amounts.
Novo Nordisk A/S Cash Flow Statement
| Dec 00 | Dec 99 | Dec 87 | |
| Net Operating Cash Flow | 658 | 493 | -- |
| Net Investing Cash Flow | (317.8) | (253.1) | -- |
| Net Financing Cash Flow | (268.7) | (26.1) | |
| Net Change in Cash | 70.2 | 213.0 | |
| Depreciation & Amortization | 129.3 | 193.9 | |
| Capital Expenditures | (295.7) | (262.2) | |
| Cash Dividends Paid | (86.2) | (76.3) |
All amounts in millions of US Dollars except per share amounts.